Zhejiang Medicine Co Ltd - Asset Resilience Ratio
Zhejiang Medicine Co Ltd (600216) has an Asset Resilience Ratio of 1.85% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 600216 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Zhejiang Medicine Co Ltd's Asset Resilience Ratio has changed over time. See 600216 equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zhejiang Medicine Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥262.29 Million | 1.85% |
| Total Liquid Assets | CN¥262.29 Million | 1.85% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Medicine Co Ltd maintains only 1.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Zhejiang Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Zhejiang Medicine Co Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.78% | CN¥250.32 Million ≈ $36.63 Million |
CN¥14.09 Billion ≈ $2.06 Billion |
-0.36pp |
| 2024-12-31 | 2.14% | CN¥294.91 Million ≈ $43.15 Million |
CN¥13.80 Billion ≈ $2.02 Billion |
-0.43pp |
| 2023-12-31 | 2.57% | CN¥328.31 Million ≈ $48.04 Million |
CN¥12.78 Billion ≈ $1.87 Billion |
-1.03pp |
| 2022-12-31 | 3.60% | CN¥447.29 Million ≈ $65.45 Million |
CN¥12.43 Billion ≈ $1.82 Billion |
-0.03pp |
| 2021-12-31 | 3.63% | CN¥454.40 Million ≈ $66.49 Million |
CN¥12.53 Billion ≈ $1.83 Billion |
+1.05pp |
| 2020-12-31 | 2.58% | CN¥270.73 Million ≈ $39.62 Million |
CN¥10.50 Billion ≈ $1.54 Billion |
-0.59pp |
| 2019-12-31 | 3.17% | CN¥328.63 Million ≈ $48.09 Million |
CN¥10.36 Billion ≈ $1.52 Billion |
+3.08pp |
| 2018-12-31 | 0.09% | CN¥8.68 Million ≈ $1.27 Million |
CN¥10.05 Billion ≈ $1.47 Billion |
+0.08pp |
| 2017-12-31 | 0.01% | CN¥778.05K ≈ $113.85K |
CN¥9.79 Billion ≈ $1.43 Billion |
0.00pp |
| 2013-12-31 | 0.01% | CN¥670.65K ≈ $98.14K |
CN¥7.56 Billion ≈ $1.11 Billion |
0.00pp |
| 2012-12-31 | 0.01% | CN¥891.75K ≈ $130.49K |
CN¥7.06 Billion ≈ $1.03 Billion |
+0.00pp |
| 2010-12-31 | 0.01% | CN¥570.00K ≈ $83.41K |
CN¥4.64 Billion ≈ $678.56 Million |
-0.08pp |
| 2006-12-31 | 0.09% | CN¥2.25 Million ≈ $329.25K |
CN¥2.53 Billion ≈ $369.98 Million |
+0.05pp |
| 2005-12-31 | 0.04% | CN¥898.23K ≈ $131.44K |
CN¥2.21 Billion ≈ $323.07 Million |
-0.02pp |
| 2004-12-31 | 0.06% | CN¥1.17 Million ≈ $171.50K |
CN¥1.84 Billion ≈ $269.09 Million |
-0.12pp |
| 2002-12-31 | 0.19% | CN¥3.06 Million ≈ $447.34K |
CN¥1.64 Billion ≈ $239.50 Million |
+0.06pp |
| 2001-12-31 | 0.13% | CN¥2.00 Million ≈ $292.66K |
CN¥1.57 Billion ≈ $229.03 Million |
-- |
About Zhejiang Medicine Co Ltd
Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, ß-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition produ… Read more